Mizutani et al. developed an original fluorescence resonance energy transfer (FRET) system for determining BCR-ABL activity and its inhibition in response to imatinib treatment in CML cells obtained by aspirating the bone marrow of CML patients. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.